Imamichi H - Search Results

1

Interleukin-27 Enhances the Potential of Reactive Oxygen Species Generation from Monocyte-derived Macrophages and Dendritic cells by Induction of p47^phox.

Sowrirajan B, Saito Y, Poudyal D, Chen Q, Sui H, DeRavin SS, Imamichi H, Sato T, Kuhns DB, Noguchi N, Malech HL, Lane HC, Imamichi T. Sowrirajan B, et al. Among authors: imamichi h. Sci Rep. 2017 Feb 27;7:43441. doi: 10.1038/srep43441. Sci Rep. 2017. PMID: 28240310 Free PMC article.

2

Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection.

Vasudevachari MB, Zhang YM, Imamichi H, Imamichi T, Falloon J, Salzman NP. Vasudevachari MB, et al. Among authors: imamichi t, imamichi h. Antimicrob Agents Chemother. 1996 Nov;40(11):2535-41. doi: 10.1128/AAC.40.11.2535. Antimicrob Agents Chemother. 1996. PMID: 8913459 Free PMC article.

3

Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.

Zhang YM, Imamichi H, Imamichi T, Lane HC, Falloon J, Vasudevachari MB, Salzman NP. Zhang YM, et al. Among authors: imamichi t, imamichi h. J Virol. 1997 Sep;71(9):6662-70. doi: 10.1128/JVI.71.9.6662-6670.1997. J Virol. 1997. PMID: 9261388 Free PMC article.

4

High-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1.

Imamichi T, Sinha T, Imamichi H, Zhang YM, Metcalf JA, Falloon J, Lane HC. Imamichi T, et al. Among authors: imamichi h. J Virol. 2000 Jan;74(2):1023-8. doi: 10.1128/jvi.74.2.1023-1028.2000. J Virol. 2000. PMID: 10623768 Free PMC article.

5

Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression.

Kovacs JA, Imamichi H, Vogel S, Metcalf JA, Dewar RL, Baseler M, Stevens R, Adelsberger J, Lambert L, Davey RT Jr, Walker RE, Falloon J, Polis MA, Masur H, Lane HC. Kovacs JA, et al. Among authors: imamichi h. J Infect Dis. 2000 Oct;182(4):1063-9. doi: 10.1086/315821. Epub 2000 Sep 5. J Infect Dis. 2000. PMID: 10979900 Clinical Trial.

6

Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.

Imamichi T, Berg SC, Imamichi H, Lopez JC, Metcalf JA, Falloon J, Lane HC. Imamichi T, et al. Among authors: imamichi h. J Virol. 2000 Dec;74(23):10958-64. doi: 10.1128/jvi.74.23.10958-10964.2000. J Virol. 2000. PMID: 11069990 Free PMC article.

7

Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy.

Imamichi H, Crandall KA, Natarajan V, Jiang MK, Dewar RL, Berg S, Gaddam A, Bosche M, Metcalf JA, Davey RT Jr, Lane HC. Imamichi H, et al. J Infect Dis. 2001 Jan 1;183(1):36-50. doi: 10.1086/317641. Epub 2000 Dec 8. J Infect Dis. 2001. PMID: 11106537

8

Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles.

Imamichi T, Murphy MA, Imamichi H, Lane HC. Imamichi T, et al. Among authors: imamichi h. J Virol. 2001 Apr;75(8):3988-92. doi: 10.1128/JVI.75.8.3988-3992.2001. J Virol. 2001. PMID: 11264389 Free PMC article.

9

Amino acid deletions are introduced into the V2 region of gp120 during independent pathogenic simian immunodeficiency virus/HIV chimeric virus (SHIV) infections of rhesus monkeys generating variants that are macrophage tropic.

Imamichi H, Igarashi T, Imamichi T, Donau OK, Endo Y, Nishimura Y, Willey RL, Suffredini AF, Lane HC, Martin MA. Imamichi H, et al. Among authors: imamichi t. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13813-8. doi: 10.1073/pnas.212511599. Epub 2002 Oct 7. Proc Natl Acad Sci U S A. 2002. PMID: 12370415 Free PMC article.

10

Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages.

Igarashi T, Donau OK, Imamichi H, Dumaurier MJ, Sadjadpour R, Plishka RJ, Buckler-White A, Buckler C, Suffredini AF, Lane HC, Moore JP, Martin MA. Igarashi T, et al. Among authors: imamichi h. J Virol. 2003 Dec;77(24):13042-52. doi: 10.1128/jvi.77.24.13042-13052.2003. J Virol. 2003. PMID: 14645561 Free PMC article.

We recently reported that the virus present in the plasma during the late macrophage phase of infection had acquired changes that specifically targeted the V2 region of gp120 (H. Imamichi et al., Proc. Natl. Acad. Sci. USA 99:13813-13818, 2002); some of these SHIV v …

We recently reported that the virus present in the plasma during the late macrophage phase of infection had acquired changes that specifical …

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

66 results

Search Page